Munich - Delayed Quote EUR

Opthea Ltd (UKJ2.MU)

3.2200

0.0000

(0.00%)

As of 8:12:04 AM GMT+1. Market Open.

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), t

GlobeNewswire yesterday

CKDXF

OPT
High Growth Tech Stocks To Watch In Australia December 2024

As the Australian market navigates a mixed landscape with the ASX200 slightly down by 0.2% and a tight labor market reflected in an unemployment rate of 3.9%, sectors like Information Technology are showing resilience with modest gains amidst broader economic challenges. In this environment, identifying high growth tech stocks involves looking for companies that can leverage innovation and adaptability to capitalize on emerging opportunities, particularly as certain sectors like Energy and...

Simply Wall St. 8 days ago

NXLLF

CKDXF

OPT
Opthea’s Wet AMD Program to be Featured at FLORetina 2024

MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. FLOReti

GlobeNewswire 24 days ago

CKDXF

OPT
Opthea to Participate in Citi 2024 Global Healthcare Conference

MELBOURNE, Australia and PRINCETON, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Fred Guerard, PharmD, Chief Executive Officer, will host one-on-one meetings with investors and participate in a panel presentation during the Citi 2024 Glob

GlobeNewswire 25 days ago

CKDXF

OPT
Opthea Appoints Kathy Connell to Board of Directors

Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced th

GlobeNewswire last month

CKDXF

OPT
High Growth Tech Stocks in Australia for November 2024

As the Australian market faces a slight downturn with the ASX200 down 1.1% and sectors like Financials and Health Care underperforming, investors are keeping a close eye on economic indicators such as the wage price index, which has shown modest growth. In this environment, identifying high-growth tech stocks becomes crucial as these companies often have the potential to outperform due to their innovative capabilities and adaptability in fluctuating market conditions.

Simply Wall St. last month

CKDXF

OPT

XROLF
Opthea’s Wet AMD Program Featured at Ophthalmology Events

17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024 Ophthalmology Innovation Summit XIV, November 23, 2024 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Opthea and soziniberce

GlobeNewswire last month

CKDXF

OPT
Opthea to Participate in November Investor Conferences

Virtual Bell Potter Healthcare Conference, November 18, 2024 Jefferies London Healthcare Conference, November 19, 2024 MELBOURNE, Australia and PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two in

GlobeNewswire last month

CKDXF

OPT
Opthea Files Notice of Annual General Meeting

Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea’s innovation agenda MELBOURNE, Australia and PRINCETON, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-relat

GlobeNewswire 2 months ago

CKDXF

OPT
Opthea Wet AMD Program to be Presented at Innovate Retina

MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during the Innovate Retina Meeting on October 17, 2024, in Chicago, Illinois. David Boyer, MD, will present an update on

GlobeNewswire 2 months ago

CKDXF

OPT
High Growth Tech Stocks in Australia to Watch

Over the last 7 days, the Australian market has remained flat, yet it is up 16% over the past year with earnings forecasted to grow by 12% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability within a stable economic environment.

Simply Wall St. 2 months ago

CKDXF

OPT

RPGRF
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company con

GlobeNewswire 2 months ago

CKDXF

OPT
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024

MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in a fireside chat and be available for one-on-one investor meetings at the UBS Virtual Ophthalmology Day 2024 being held on Oc

GlobeNewswire 2 months ago

CKDXF

OPT
Opthea Joins the S&P/ASX 300 Index

MELBOURNE, Australia and PRINCETON, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that the Company joins the S&P/ASX 300 Index, effective Monday, September 23, 2024, prior to market open in Australia. “Opthea’s addition to the S&P/ASX 300 Ind

GlobeNewswire 2 months ago

CKDXF

OPT
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept

Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in early 2025 MELBOURNE, Australia and PRINCETON, N.J., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macula

GlobeNewswire 3 months ago

CKDXF

OPT
Exploring 3 High Growth Tech Stocks in Australia

Over the last 7 days, the Australian market has dropped 1.7%, driven by a decline of 5.4% in the Materials sector, although it remains up 10% over the past year with earnings expected to grow by 12% per annum over the next few years. In this context, identifying high-growth tech stocks that can outperform despite short-term market fluctuations is crucial for investors seeking robust long-term returns.

Simply Wall St. 3 months ago

CKDXF

OPT

PMCUF
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight

MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced scientific presentations and a non-CME educational lunch symposium highlighting sozinibercept’s potential to become the first therapy in 20 years to improve vis

GlobeNewswire 3 months ago

CKDXF

OPT
Opthea Announces Executive Leadership Changes and Senior Hires

Daniel Geffken appointed Chief Financial Officer ad interim Mike Campbell appointed Chief Commercial Officer Three senior leaders appointed for Biometrics, Clinical Operations and Market Access MELBOURNE, Australia and PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical Company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degene

GlobeNewswire 3 months ago

CKDXF

OPT
Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference

MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present and participate in one-on-one investor meetings at the following two investor conferences in September 2024: H.C. Wainwright 26th A

GlobeNewswire 3 months ago

CKDXF

OPT
Exploring Three High Growth Tech Stocks In Australia

The ASX200 closed up 0.58% at 8,091.9 points, with the last day of the earnings season bringing mixed results across various sectors, while retail sales data from July showed a plateau in activity. As analysts digest these developments and consider their implications for interest rates, it is crucial to identify high-growth tech stocks that exhibit strong fundamentals and resilience in a fluctuating market environment like Australia's.

Simply Wall St. 3 months ago

SKLTF

SKLTY

CKDXF

Performance Overview

Return	UKJ2.MU	S&P/ASX 200 [XJO]
YTD	+23.85%	+6.27%
1-Year	+38.79%	+7.02%
3-Year	-48.48%	+10.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Opthea Ltd (UKJ2.MU)

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

High Growth Tech Stocks To Watch In Australia December 2024

Opthea’s Wet AMD Program to be Featured at FLORetina 2024

Opthea to Participate in Citi 2024 Global Healthcare Conference

Opthea Appoints Kathy Connell to Board of Directors

High Growth Tech Stocks in Australia for November 2024

Opthea’s Wet AMD Program Featured at Ophthalmology Events

Opthea to Participate in November Investor Conferences

Opthea Files Notice of Annual General Meeting

Opthea Wet AMD Program to be Presented at Innovate Retina

High Growth Tech Stocks in Australia to Watch

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

Opthea to Participate in the UBS Virtual Ophthalmology Day 2024

Opthea Joins the S&P/ASX 300 Index

Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept

Exploring 3 High Growth Tech Stocks in Australia

Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight

Opthea Announces Executive Leadership Changes and Senior Hires

Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference

Exploring Three High Growth Tech Stocks In Australia

Performance Overview